Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Concurrent Hyperthermia and Chemoradiotherapy in LAPC: Phase II Study (HEATPAC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02439593
Recruitment Status : Recruiting
First Posted : May 12, 2015
Last Update Posted : August 1, 2017
Sponsor:
Collaborator:
University of Zurich
Information provided by (Responsible Party):
Prof. Dr. med. Niloy Ranjan Datta, Kantonsspital Aarau

Tracking Information
First Submitted Date  ICMJE May 4, 2015
First Posted Date  ICMJE May 12, 2015
Last Update Posted Date August 1, 2017
Actual Study Start Date  ICMJE January 1, 2017
Estimated Primary Completion Date June 30, 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: May 8, 2015)
Overall survival (at 1 year) [ Time Frame: From date of randomization until the date of death from any cause assesed at 1 year or whichever is earlier ]
Overall survival
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: May 8, 2015)
  • Progression free survival (as per Response Evaluation Criteria in Solid Tumours (RECIST), v1.1) [ Time Frame: From date of randomization until the first docemented disease progression as evident on CECT / PET-CT / MRI as per RECIST criteria (v1.1), whichever came first assessed upto the end of study period of 60 weeks ]
    Progression free survival
  • Patterns of failure : both local and systemic (as per RECIST, v1.1) [ Time Frame: From date of randomization until the disease progression either locally or at distant sites as evident on CECT / PET-CT / MRI as per RECIST criteria (v1.1), whichever came first assessed upto the end of study period of 60 weeks ]
    Patterns of failure : both local and systemic
  • Acute and late morbidity (as per Common Toxicity Criteria for Adverse Effects (CTCAE) v4.03) [ Time Frame: Acute or late morbidity from date of randomization until the patients death from any cause as per the CTCAE v4.03 whichever came first assessed upto the end of study period of 60 weeks ]
    Acute and late morbidity that are ascribed to treatment
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Concurrent Hyperthermia and Chemoradiotherapy in LAPC: Phase II Study
Official Title  ICMJE A Phase II Randomized Study of Concurrent Hyperthermia and Chemoradiotherapy vs. Chemoradiotherapy Alone Following Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer (HEATPAC)
Brief Summary This is a phase II randomized study of concurrent chemoradiotherapy and local hyperthermia (study group) versus chemoradiotherapy alone (control group) following neoadjuvant chemotherapy in locally advanced pancreatic cancer. Each of the treatment arm would have 39 patients based on the expected overall 1 year survival advantage of +20% over the control group (p0=40%).
Detailed Description

This phase II randomized trial is a part of the comprehensive protocol designed for the locally advanced pancreatic cancers (LAPC). All patients of LAPC, fulfilling the following criteria of "Unresectable LAPC" would be considered to be eligible for enrolment in the study.

These include:

  1. Major venous infiltration / thrombosis of the portal vein or superior mesenteric vein extending for several centimeters (precluding vein resection and reconstruction)
  2. Tumor encasement (≥180°) of the superior mesentric artery or proximal hepatic artery
  3. Tumor abutment (<180°) of the celiac trunk
  4. Tumor invasion of the aorta
  5. Presence of metastasis to lymph nodes beyond the field of resection All patients would be reviewed at the Pancreas Cancer Tumor Board, University Hospital Zurich and those fulfilling the above condition/s would be considered for the study protocol of LAPC. Following a detailed work up, all eligible patients with primary tumours more than 4 cm would be considered for HEATPAC study.

Patients would be randomized by random digit using a double blinded strategy into either (a) Control group : Treated with concurrent chemoradiotherapy or (b) Study group: Treated with local hyperthermia along with concurrent chemoradiotherapy.

Treatment in both groups would be initiated with 4 cycles of neo-adjuvant chemotherapy (FOLFIRINOX). At completion of 4 cycles of neo-adjuvant FOLFIRINIOX, patients would be evaluated by PET-CT, 3-4 week following the last cycle of FOLFIRINIOX. Patients in control group would be taken up for concurrent gemcitabine (400 mg / sq.m weekly) along with loco-regional radiotherapy by SIB-IMRT to a dose of 50.4 Gy in 28 fractions. Patients in the study group would be receiving loco-regional hyperthermia to a temperature of 40-41°C, weekly for 1 hour before gemcitabine and before radiotherapy. The gemcitabine and in loco-regional radiotherapy in study group would be similar to that of the control group.

Following the completion of this treatment, patients of both groups would be considered for 8 cycles of adjuvant FOLFIRINOX and followed up with both clinical, heamatological and imaging studies as detailed in the study protocol.

Primary endpoint:

  1. Overall survival at 1 year
  2. To assess the acute and the late morbidities associated with hyperthermia and chemoradiotherapy in concurrent chemoradiotherapy compared to concurrent chemoradiotherapy alone.

Secondary endpoints:

  1. To compare the disease free survival in patients of locally advanced pancreatic cancers following neoadjuvant chemotherapy with FOLOFIRINOX treated with hyperthermia and chemoradiotherapy versus chemoradiotherapy alone.
  2. To assess the patterns of failure (both local and systemic) in patients of both treatment arms.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
Hyperthermia with chemoradiotherapy vs. Chemoradiotherapy alone
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Cancer Pancreas
Intervention  ICMJE
  • Other: Chemoradiotherapy (CTRT)
    CTRT arm: Locoregional radiotherapy along with concurrent weekly gemcitabine
  • Other: Thermochemoradiotherapy (CTRTHT)
    Locoregional hyperthermia with concurrent chemoradiotherapy with weekly gemcitabine
Study Arms  ICMJE
  • Active Comparator: Chemoradiotherapy (CTRT) (Control Group)

    Intervention type:

    Drug and Radiation

    Intervention name:

    Drug (Gemcitabine) Radiation (Loco-regional radiotherapy by SIB-IMRT)

    Intervention description:

    Radiotherapy: 5 days a week (Days 1 to 5) of each week for 5.5 weeks (28 fractions), Total dose: 50.4 Gy at 1.8 Gy /fr. over 5.5 weeks Chemotherapy: Gemcitabine (400 mg / sq. m) would be administered weekly 24 hours after hyperthermia on Day 2 and after radiotherapy every week on D2

    Intervention: Other: Chemoradiotherapy (CTRT)
  • Experimental: Thermochemoradiotherapy (CTRTHT)

    Intervention type:

    Drug, Radiation and Hyperthermia

    Intervention name:

    Drug (Gemcitabine) Radiation (Loco-regional radiotherapy by SIB-IMRT) Hyperthermia (Loco-regional hyperthermia),

    Intervention description:

    Radiotherapy: 5 days a week (Days 1 to 5) of each week for 5.5 weeks (28 fractions), Total dose: 50.4 Gy at 1.8 Gy /fr. over 5.5 weeks Chemotherapy: Gemcitabine (400 mg / sq. m) would be administered weekly 24 hours after hyperthermia on Day 2 and after radiotherapy every week on D2 Hyperthermia: Weekly Local hyperthermia before radiotherapy on D1 of every week, 41-43°C for 60 mins, once every week

    Intervention: Other: Thermochemoradiotherapy (CTRTHT)
Publications * Datta NR, Pestalozzi B, Clavien PA, Siebenhüner A, Puric E, Khan S, Mamot C, Riesterer O, Knuchel J, Reiner CS, Bodis S; members of the HEATPAC Trial Group. "HEATPAC" - a phase II randomized study of concurrent thermochemoradiotherapy versus chemoradiotherapy alone in locally advanced pancreatic cancer. Radiat Oncol. 2017 Nov 21;12(1):183. doi: 10.1186/s13014-017-0923-8.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: May 8, 2015)
78
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE December 31, 2021
Estimated Primary Completion Date June 30, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Patients of locally advanced pancreatic cancer with

    • Major venous infiltration / thrombosis of the portal vein or superior mesenteric vein extending for several centimeters
    • Tumor encasement (≥180°) of the superior mesentric artery or proximal hepatic artery
    • Tumor abutment (<180°) of the celiac trunk
    • Tumor invasion of the aorta
    • Presence of metastasis to lymph nodes beyond the field of resection
  2. Histopathologically proven ductal adenocarcinoma of the pancreas (biopsy /cytology)
  3. Eastern Cooperative Oncology Group (ECOG) performance scale 0 and 1
  4. Age: 18 to 80 years
  5. At least one of the diameters of the primary tumor or regional lymph node or both should be greater than 4 cm, as confirmed on contrast-enhanced computed tomography (CECT).
  6. Patients, have primary tumor or regional lymph node or both lesser than 4 cm, as confirmed on CECT but have specific medical contraindications to stereotactic body radiation therapy or irreversible electroporation or as per patient's preference could be considered for HEATPAC.
  7. No evidence of any distant metastasis
  8. Patients with microscopic peritoneal carcinomatosis, detected on laparoscopy following 4 cycles on neo-adjuvant FOLFIRINOX would be included.
  9. Estimated life expectancy of at least 6 months
  10. Adequate kidney functionality defined as creatinine clearance >50ml/min
  11. Adequate liver functionality defined as total bilirubin ≤ 2x of the upper limit of normal
  12. Adequate bone marrow reserves: White blood cell count ≥ 2.5 x 10˄9/L, Platelet count ≥ 100 x 10˄9/L, Hemoglobin ≥ 8.0g/L
  13. Women of child-bearing age must secure sufficient contraception control during the clinical trial and six months after the clinical trial is completed
  14. For females of child bearing potential, negative pregnancy test within 2 week prior to randomization.
  15. Female patients should not be lactating
  16. Absence of psychological, familial, sociological or geographical condition that could potentially hamper compliance with the study protocol and follow-up schedule

Exclusion Criteria:

  1. Histopathology other than ductal adenocarcinoma pancreas
  2. Prior radiotherapy to the site of treatment
  3. Patients with unequivocal distant metastasis including liver
  4. Patients with gross peritoneal carcinomatosis on laparoscopy
  5. No prior or concurrent malignancies other than surgically treated squamous cell or basal cell carcinoma of the skin
  6. No serious medical illness which would prevent informed consent or limit survival to less than 2 years
  7. Active uncontrolled bacterial, viral or fungal infections until these conditions are corrected or controlled.
  8. Psychiatric or addictive disorders or other conditions that would preclude the patient from meeting the study requirements.
  9. Patients having metal implants, pacemakers or clustered markers.
  10. Metallic endobiliary stenting would be a contraindication, hence plastic stents may be used if biliary drainage is indicated.
  11. Patient with a history of myocardial infarction within the past 12 months
  12. No connective disease disorders that contraindicate radiotherapy, e.g., Scleroderma
  13. Pre-existing grade 2 peripheral neuropathy
  14. Any known contraindication or hypersensitivity to the chemotherapeutic agents
  15. Pregnancy, lactation period or lack of reliable contraception
  16. Any other disease or therapy, which, present a risk to the patient or which are not compatible with the aims of the clinical trial
  17. Patients would express their inability to travel on their own to Kantonsspital Aarau, (KSA) for hyperthermia treatment
  18. Indications that the person concerned will be noncompliant to the clinical trial plan because of unwillingness to cooperate or difficulties in keeping the check-up appointments
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 80 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Niloy R Datta, MD,DNB +41628422088 niloyranjan.datta@ksa.ch
Contact: Stephan Bodis, MD +41628385371 stephan.bodis@ksa.ch
Listed Location Countries  ICMJE Switzerland
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02439593
Other Study ID Numbers  ICMJE HEATPAC
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Prof. Dr. med. Niloy Ranjan Datta, Kantonsspital Aarau
Study Sponsor  ICMJE Kantonsspital Aarau
Collaborators  ICMJE University of Zurich
Investigators  ICMJE
Principal Investigator: Niloy R Datta, MD,DNB Kantonsspital Aarau
PRS Account Kantonsspital Aarau
Verification Date July 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP